Skip to content

Relay Therapeutics rallies 7% on EcoR1 pitch

September 23, 2020

Relay Therapeutics (RLAY +7.3%) is up, albeit on below-average volume, in apparent response to a presentation on the company by fundamental shop EcoR1 Capital at the Sohn Conference.

The company debuted on July 16 at $20. Shares are currently exchanging hands at $47.13, up 136%.

It develops small molecule therapies leveraging its know-how in protein motion. Its Dynamo platform, which integrates experimental and computational approaches, enables it to more effectively identify previously undruggable protein targets.

Lead candidates are RLY-1971, an inhibitor of a protein called SHP2 (Src homology region 2 domain-containing phosphatase-2), and RLY-4008, an inhibitor of a protein called fibroblast growth factor receptor 2 (FGFR2), both in Phase 1 development for the potential treatment of solid tumors.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: